Carl LeBel

Carl LeBel

Company: Frequency Therapeutics

Job title: Chief Development Officer


Results of Four Single-Dose Trials of FX-322 Show Improved Speech Perception 3:15 pm

• This presentation showcases clinical case studies of FX-322, a small-molecule combination designed to regenerate cochlear hair cells • This summary combines the results of four single-dose trials of FX-322, three of which showed speech perception improvements in some patients • These positive results support the continued evaluation of FX-322 in multiple populations to determine…Read more

day: Day Two

Panel Discussion: Optimizing Functional Testing & Outcomes Measures in Clinical Trials 6:00 pm

This panel will be a structured conversation designed to answer key questions such as: • What is the correct choice of outcome measures for novel hearing therapeutics? • What are the early signals of efficacy and how are functional changes in hearing best measured? • Evaluating the rationale behind why companies have chosen to opt…Read more

day: Day One

Clinical Trial Design Considerations for Inner Ear Therapeutics 5:00 pm

• Protocol design considerations for hearing loss trials • Choice of outcome measures and establishing a clinically meaningful improvement level • Patient selection strategies to optimize target population and patient homogeneityRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.